Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to Buy Now. On March 20, Jefferies reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) with a price target of $1,300.
The rating is based on the company’s prescription data for GLP-1 medications. Oral Wegovy had roughly 89,300 IMS prescriptions and 76,800 Symphony prescriptions in the 10th week of its launch. The data outpace comparable launches of injectable Wegovy and Zepbound.
On the other hand, data from other GLP-1 drugs witnessed declines, including Zepbound falling 3% to 17,100 prescriptions, Mounjaro dropping to 13,100 after a 2% decline, and injectable Wegovy decreased 3% to 9,710.
The firm noted that the data for oral Wegovy is encouraging for Eli Lilly’s Orforglipron, ahead of its PDUFA date on April 10, 2026. The firm projects $2 billion in 2026 Orforglipron revenue, exceeding the $1.55 billion consensus, against Lilly’s guidance of $80 billion to $83 billion total revenue.
Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 High-Flying Penny Stocks to Buy and 10 Cheap Stocks to Buy for High Returns in 2026.
Disclosure: None. Follow Insider Monkey on Google News.
-1024x683.jpg "The Left Tries to Paint America 250 in the Blues")
-1024x683.jpg "Strait Outta Hormuz: Getting the Iran Oil Story Straight")
